|NASDAQ: CFRX||Healthcare / Biotechnology / USA|
|1.98||-0.0201||-1.00%||Vol 26.51K||1Y Perf -46.52%|
|Mar 22nd, 2023 12:57 DELAYED|
|0.09 4.50%||- -|
|Target Price||3.67||Analyst Rating||Moderate Buy 2.00|
|Potential %||85.36||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-/-/-||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-/-/-||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-||Income Ranking||— -|
|Price Range Ratio 52W %||0.06||Earnings Rating||Strong Sell|
|Market Cap||2.57M||Earnings Date||23rd Mar 2023|
Today's Price Range
5 Year PE Ratio Range
|3 Months||1 904.01%|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Valuation||Value||Industry||S&P 500||US Markets|
|-10 221 100.00|
|Financial Strength||Value||Industry||S&P 500||US Markets|
|Profitability||Value||Industry||S&P 500||US Markets|
|Revenue||Value||Industry||S&P 500||US Markets|
|Dividends||Value||Industry||S&P 500||US Markets|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||23rd Mar 2023|
|Estimated EPS Next Report||-27.20|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||116.88K|
|Avg. Monthly Volume||1.54M|
|Avg. Quarterly Volume||10.02M|
ContraFect Corporation (NASDAQ: CFRX) stock closed at 2 per share at the end of the most recent trading day (a 11.73% change compared to the prior day closing price) with a volume of 152.28K shares and market capitalization of 2.57M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 24 people. ContraFect Corporation CEO is Roger J. Pomerantz.
The one-year performance of ContraFect Corporation stock is -46.52%, while year-to-date (YTD) performance is 1983.33%. CFRX stock has a five-year performance of -89.74%. Its 52-week range is between 1.75 and 363.2, which gives CFRX stock a 52-week price range ratio of 0.06%
ContraFect Corporation currently has a PE ratio of -0.10, a price-to-book (PB) ratio of 0.44, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -134.22%, a ROC of -212.65% and a ROE of -285.71%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from ContraFect Corporation, there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-27.20 for the next earnings report. ContraFect Corporation’s next earnings report date is 23rd Mar 2023.
The consensus rating of Wall Street analysts for ContraFect Corporation is Moderate Buy (2), with a target price of $3.67, which is +85.36% compared to the current price. The earnings rating for ContraFect Corporation stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ContraFect Corporation has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ContraFect Corporation has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.64, ATR14 : 0.43, CCI20 : -87.74, Chaikin Money Flow : -0.80, MACD : 0.06, Money Flow Index : 22.77, ROC : -36.51, RSI : 47.88, STOCH (14,3) : 15.72, STOCH RSI : 0.58, UO : 41.55, Williams %R : -84.28), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ContraFect Corporation in the last 12-months were:
|Analyst Ratings||Current||1 M ago||3 M ago|
|Summary Rating||Moderate Buy||Moderate Buy||Moderate Buy|
ContraFect Corp is a cinical-stage biotechnology company which focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases including those caused by drug-resistant pathogens, particularly treated in hospital settings. The company has developed advanced lysin product candidate, CF-301 for the treatment of Staph aureus bacteremia, including endocarditis. It also emphasizes on addressing drug-resistant infections using product candidates from its lysin and monoclonal antibody platforms that target conserved regions of either bacteria or viruses. The company operates through a single segment being the Development of therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases.
CEO: Roger J. Pomerantz
Telephone: +1 914 207-2300
Address: 28 Wells Avenue, Yonkers 10701, NY, US
Number of employees: 24
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
Looks like you are using AdBlock.
The revenue earned from advertising enables us to provide the quality content you are trying to reach on this website. In order to view this page, please disable AdBlock or purchase Premium.
Sign in if you already have Premium account.
This could take some time, please wait.